Combination of acarbose and ezetimibe prevents non-alcoholic fatty liver disease: a break of intestinal insulin resistance?
Rudovich
Natalia N
NN
Weickert
Martin O
MO
Machann
Juergen
J
Pfeiffer
Andreas F H
AF
D020909:Acarbose / Q000008:administration & dosage*; D000924:Anticholesteremic Agents / Q000008:administration & dosage*; D001384:Azetidines / Q000008:administration & dosage*; D004359:Drug Therapy, Combination; D000069438:Ezetimibe; D005234:Fatty Liver / Q000188:drug therapy / Q000378:metabolism / Q000517:prevention & control*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007333:Insulin Resistance
D000924:Anticholesteremic Agents; D001384:Azetidines; D007004:Hypoglycemic Agents; D000069438:Ezetimibe; D020909:Acarbose